Aktis Oncology, Inc. is a clinical stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations including those not addressed by existing platform technologies. The company has built a proprietary miniprotein radioconjugate platform designed to selectively deliver tumor killing radioisotopes to targeted tumors with high tumor penetration and prolonged tumor retention while being rapidly cleared from normal organs and tissues to minimize systemic radiation exposure. Its lead product candidate is [225 Ac]Ac-AKY 1189 which targets Nectin 4 expressing solid tumors such as locally advanced or metastatic urothelial cancer, breast cancer, non small cell lung cancer, colorectal cancer, and cervical cancer. A second program is [225 Ac]Ac-AKY 2519 targeting B7 H3 expressing solid tumors including prostate, lung, and breast cancers. The platform aims to broaden the number of tumor targets addressable by radiopharmaceuticals beyond the traditional targets such as prostate specific membrane antigen and somatostatin 2 receptor. By doing so Aktis Oncology seeks to expand the commercial uptake of radiopharmaceuticals beyond the traditional nuclear medicine setting into the broader clinical oncology setting.
As a clinical stage company Aktis Oncology has not yet generated product sales revenue. Revenue is derived primarily from collaboration agreements license arrangements and milestone payments. The collaboration with Eli Lilly provides an up front cash payment of $60 million, an equity investment, and the potential to receive up to $1.2 billion upon achievement of preclinical, clinical, regulatory, and commercial milestones as well as tiered royalties on net sales. Additional license agreements with the Institute for Protein Innovation, TRIUMF, and the University of Minnesota provide up front fees, milestone payments, and low single digit royalties on net sales. No product sales have been reported to date.
Aktis Oncology operates in the radiopharmaceuticals segment of the oncology market which includes approved products such as Pluvicto, Lutathera, and Xofigo. Key competitors developing targeted alpha emitting radiopharmaceuticals include Actinium Pharmaceuticals, Fusion Pharmaceuticals, Point Biopharma, RayzeBio, Telix Pharmaceuticals, and several others. The company differentiates itself through its proprietary miniprotein platform which enables high affinity binding to a broad range of tumor targets, rapid clearance from normal tissues, and reduced kidney exposure compared to peptide based radioconjugates. The integration of artificial intelligence and machine learning into target selection and miniprotein design further enhances the speed and precision of candidate discovery. Internal manufacturing capabilities including a planned cGMP facility and partnerships with multiple domestic and international isotope suppliers provide supply chain redundancy and flexibility. These advantages position Aktis Oncology to capture a share of the growing radiopharmaceuticals market which is projected to exceed 26 billion dollars in sales by 2032.
The company's current customers consist of collaboration partners such as Eli Lilly, isotope suppliers including NorthStar Medical Technologies, TerraPower Isotopes, and Niovave, and contract manufacturing organizations that support clinical trial material production. Clinical trial sites including hospitals and cancer centers in the United States and abroad receive the investigational drug for studies in patients with urothelial, breast, lung, colorectal, and cervical cancers. Patients participating in these trials represent the end users of the investigational product. Upon commercial approval Aktis Oncology expects to serve hospitals, oncology clinics, and other healthcare providers that administer radiopharmaceutical therapies to cancer patients.